NeuBase lays off 60% of employees as it swaps out antisense focus for gene editing tech endorsed by George Church
Geneticist and serial entrepreneur Dietrich Stephan had hoped that his antisense oligonucleotide platform at NeuBase Therapeutics could expand the field that Ionis pioneered to new areas. But in the end, he concluded now is not the right time to explore it.
NeuBase has decided to shift its whole focus to gene editing, deferring preclinical activities for antisense programs targeting myotonic dystrophy type 1, Huntington’s disease and KRAS-mutant cancers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.